Cargando…

KLF5 controls glutathione metabolism to suppress p190-BCR-ABL+ B-cell lymphoblastic leukemia

High-risk B-cell acute lymphoblastic leukemia (B-ALL) remains a therapeutic challenge despite advances in the use of tyrosine kinase inhibitors and chimeric-antigen-receptor engineered T cells. Lymphoblastic-leukemia precursors are highly sensitive to oxidative stress. KLF5 is a member of the Krüppe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Cuiping, D'Alessandro, Angelo, Wellendorf, Ashley M., Mohmoud, Fatima, Serrano-Lopez, Juana, Perentesis, John P., Komurov, Kakajan, Alexe, Gabriela, Stegmaier, Kimberly, Whitsett, Jeffrey A., Grimes, H. Leighton, Cancelas, Jose A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6049869/ https://www.ncbi.nlm.nih.gov/pubmed/30038712 http://dx.doi.org/10.18632/oncotarget.25667

Ejemplares similares

c-Fos and Dusp1 confer non-oncogene addiction in BCR-ABL induced leukemia
por: Kesarwani, Meenu, et al.
Publicado: (2017)

Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia
por: Kaur, Pavinder, et al.
Publicado: (2007)

Emergence of BCR-ABL1 (p190) in Acute Myeloid Leukemia Post-Gilteritinib Therapy
por: Kim, Heejeong, et al.
Publicado: (2023)

Frequency of p190 and p210 BCR-ABL rearrangements and survival in Brazilian adult patients with acute lymphoblastic leukemia
por: de França Azevedo, Ilana, et al.
Publicado: (2014)

S6K1 determines the metabolic requirements for BCR-ABL survival
por: Barger, Jennifer F., et al.
Publicado: (2012)

The targetable role of herpes virus-associated ubiquitin-specific protease (HAUSP) in p190 BCR-ABL leukemia
por: Carrà, Giovanna, et al.
Publicado: (2016)

Chronic Myeloid Leukemia With P190 BCR-ABL Translocation and Persistent Moderate Monocytosis: A Case Report
por: Gatti, Arianna, et al.
Publicado: (2018)

Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets
por: Adnan-Awad, Shady, et al.
Publicado: (2020)

c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells
por: Waldron, Todd, et al.
Publicado: (2011)

Coexistence of P190 and P210 BCR/ABL transcripts in chronic myeloid leukemia blast crisis resistant to imatinib
por: Junmei, Zhao, et al.
Publicado: (2015)

Differential signaling networks of Bcr–Abl p210 and p190 kinases in leukemia cells defined by functional proteomics
por: Reckel, S, et al.
Publicado: (2017)

The signaling axis atypical protein kinase C λ/ι-Satb2 mediates leukemic transformation of B-cell progenitors
por: Nayak, R. C., et al.
Publicado: (2019)

Jak2/STAT6/c-Myc pathway is vital to the pathogenicity of Philadelphia-positive acute lymphoblastic leukemia caused by P190(BCR-ABL)
por: Qin, Run, et al.
Publicado: (2023)

Adult acute megakaryoblastic leukemia: rare association with cytopenias of undetermined significance and p210 and p190 BCR–ABL transcripts
por: Dima, Delia, et al.
Publicado: (2017)

P190(BCR-ABL1) in a Patient with Philadelphia Chromosome Positive T-Cell Acute Lymphoblastic Leukemia: A Rare Case Report and Review of Literature
por: Kohla, Samah, et al.
Publicado: (2021)

Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia
por: Kim, Jaeseung C., et al.
Publicado: (2023)

Optimal Molecular Methods in Detecting p190(BCR-ABL) Fusion Variants in Hematologic Malignancies: A Case Report and Review of the Literature
por: Sonu, Rebecca J., et al.
Publicado: (2015)

P190(BCR-ABL) Chronic Myeloid Leukemia Following a Course of S-1 Plus Oxaliplatin Therapy for Advanced Gastric Adenocarcinoma
por: Wang, Hua, et al.
Publicado: (2017)

A Rare Case of p190 BCR-ABL Chronic Myeloid Leukemia With a Very Good Response to Tyrosine Kinase Inhibitors
por: Gandhe, Nalinikumari, et al.
Publicado: (2021)

A case of e1a2 (minor, P190) BCR-ABL1-positive chronic myeloid leukemia in Korea
por: Choi, Yu Jeong, et al.
Publicado: (2021)

A Rare Case of p190 BCR-ABL B-cell Acute Lymphocytic Leukemia With Excellent Response to Hyper-CVAD and Ponatinib
por: DeRon, Nathan, et al.
Publicado: (2022)

An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system
por: Choi, Kwangmin, et al.
Publicado: (2017)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)

Coexistence of p190 BCR/ABL Transcript and CALR 52-bp Deletion in Chronic Myeloid Leukemia Blast Crisis: A Case Report
por: Seghatoleslami, Mohammad, et al.
Publicado: (2016)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

Revealing static and dynamic modular architecture of the eukaryotic protein interaction network
por: Komurov, Kakajan, et al.
Publicado: (2007)

Patterns of human gene expression variance show strong associations with signaling network hierarchy
por: Komurov, Kakajan, et al.
Publicado: (2010)

An Unprecedented Case of p190 BCR-ABL Chronic Myeloid Leukemia Diagnosed during Treatment for Multiple Myeloma: A Case Report and Review of the Literature
por: Miki, Kosuke, et al.
Publicado: (2018)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia
por: Fei, Fei, et al.
Publicado: (2010)

Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive cases
por: Abdelmagid, Maymona G., et al.
Publicado: (2022)

BCR: a new target in resistance mediated by BCR/ABL-315I?
por: Haberbosch, Isabella, et al.
Publicado: (2016)

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
por: Deng, Xianming, et al.
Publicado: (2010)

An In-House Method for Molecular Monitoring of BCR-ABL
por: Sercan, Hakkı Ogün, et al.
Publicado: (2012)

Depression of oncogenecity by dephosphorylating and degrading BCR-ABL
por: Gao, Miao, et al.
Publicado: (2016)

Enhanced MAPK signaling is essential for CSF3R induced leukemia
por: Rohrabaugh, Sara, et al.
Publicado: (2016)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_05i33466r6dtdgu3prjoa4onfi